



Published in final edited form as:

Nat Neurosci. 2016 December ; 19(12): 1599–1609. doi:10.1038/nn.4421.

Mechanism to develop inflammasome-independent and interferon- β -resistant EAE with neuronal damages

Makoto Inoue^{1,2}, Po-han Chen³, Stephen Siecinski⁴, Qi-jing Li¹, Chunlei Liu^{5,6}, Lawrence Steinman⁷, Simon G. Gregory⁴, Eric Benner⁸, and Mari L. Shinohara^{1,3,*}

¹Department of Immunology, Duke University School of Medicine, Durham, NC 27710

²Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802

³Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710

⁴Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC 27701

⁵Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, CA 94720

⁶Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720

⁷Department of Neurology and Neurological Sciences, Stanford University, Beckman Center for Molecular Medicine, Stanford, CA 94305-5316

⁸Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710

Abstract

Inflammation induced by innate immunity influences the development of T cell-mediated autoimmunity in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). We found that strong activation of innate immunity induced NLRP3 inflammasome-independent and interferon- β (IFN β)-resistant EAE (termed Type-B EAE), whereas EAE induced by weak activation of innate immunity requires NLRP3 inflammasome and is sensitive to IFN β treatment. Instead, an alternative inflammatory mechanism, including membrane-bound lymphotoxin- β receptor (LT β R) and CXCR2, is involved in Type-B EAE development; and Type-B EAE is ameliorated by antagonizing the receptors. Relative expression of *Ltbr* and *Cxcr2* genes was indeed enhanced in IFN β -resistant MS patients. Importantly, remission is minimal in Type-B EAE due to neuronal damages induced by semaphorin 6B

*Correspondence to Dr. Mari L. Shinohara, Department of Immunology, Duke University Medical Center, Durham, NC 27710. Telephone: +1-919-613-6977, Fax: +1-919-684-8982, mari.shinohara@duke.edu.

Author contributions

M.I. and M.L.S. designed the study, analyzed data, and wrote the manuscript. M.I. performed most of the experiments. P.C. performed methylation assay. S.G.G. selected RRMS patient samples from the MURDOCK study cohorts. S.S. performed qPCR analysis for RRMS patient samples. C.L. performed MRI analysis. E.B. assisted neuron imaging analyses. C.L., Q.L., L.S., S.G. and E.B. contributed critical discussion for data and analysis.

Competing Financial Interests Statement

The authors declare no competing financial interests.

upregulation on CD4⁺ T cells. Our data reveal a novel inflammatory mechanism by which IFN β -resistant EAE subtype develops.

Introduction

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease accompanied by demyelination of the central nervous system (CNS). As a multifactorial heterogeneous disease, MS is difficult to treat. Some MS patients show CNS axonal damage, which may occur independently of chronic demyelination¹. Disease heterogeneity also extends to drug response. For example, IFN β , a first-line treatment to MS patients for over 15 years in relapsing-remitting MS (RRMS), is not effective for 7–49% of RRMS patients². Mechanisms underlying the heterogeneity in the disease etiology and patients' responses to treatments are largely unknown.

Experimental autoimmune encephalomyelitis (EAE), an animal model of MS, has provided valuable insight to some of the pathological mechanisms of MS and has led to the development of glatiramer acetate and natalizumab as therapeutics^{3–5}. However, there is an inherent challenge to using EAE as a model for studying disease heterogeneity without introducing confounders such as an alternative mouse strain(s), manipulating gene expression, or using unconventional reagent(s)⁶.

The NLRP3 inflammasome is a crucial target of IFN β treatment in EAE. We have previously reported that IFN β suppresses NLRP3 inflammasome activity by reducing active Rac-1 and mitochondrial ROS generation⁷. The NLRP3 inflammasome plays a critical role in EAE development, as demonstrated that *Nlrp3*^{-/-} mice are resistant to EAE^{8, 9}. The lack of the NLRP3 inflammasome in antigen presenting cells (APCs) dampens expression of chemokines and chemokine receptors on T helper cells and APCs, and fails their migration to the CNS⁸. Nevertheless, it is also known that EAE can develop without the NLRP3 inflammasome^{7, 10}. It is, however, elusive what is an alternative mechanistic pathway to induce EAE without the NLRP3 inflammasome, and whether the NLRP3 inflammasome-independent EAE is functionally and phenotypically distinct from typical NLRP3 inflammasome-dependent EAE. Understanding these mechanisms may represent a pivotal step toward understanding heterogeneity in EAE, and possibly in MS too.

In this study, we sought to reveal the molecular and cellular mechanisms that govern the pathophysiology of Type-B EAE by dissecting mechanisms to induce an NLRP3 inflammasome-independent EAE subtype, which is induced by aggressive immunization using high doses of heat-killed Mycobacteria (*Mtb*) without introducing confounding factors. For Type-B EAE development, our results suggested the critical involvement and enhanced expression of lymphotoxin- β receptor (LT β R) and a chemokine receptor CXCR2, which detect membrane-bound lymphotoxin (mLT) and CXCL1, respectively. The pathway including LT β R and CXCR2 allows mice to bypass NLRP3 inflammasome-mediated inflammation for EAE induction. Although Type-B EAE does not respond to IFN β treatment, blockade of LT β R or CXCR2 successfully ameliorates the disease. Furthermore, relative levels of *Ltbr* and *Cxcr2* were found to be increased in IFN β non-responder MS

patients. Type-B EAE undergoes irreversible disease phenotype due to the neuronal damage mediated by semaphorin 6B (Sema6B) upregulation in CD4⁺ T cells in the CNS.

RESULTS

NLRP3 is dispensable for EAE high adjuvant doses

We titrated the amounts of *Mtb* (*i.e.*, adjuvant) used in complete Freund's adjuvant (CFA) to induce EAE, and evaluated disease severity in *Nlrp3*^{-/-} mice (in the C57BL6 background). *Nlrp3*^{-/-} mice were used, because they hardly developed EAE using the standard EAE induction method with 200 µg *Mtb* in CFA (Method 1 in Supplementary Figure 1a, b), as previously reported⁸. However, either repeated immunization or an increased *Mtb* dosage (400 µg) was sufficient to induce severe EAE in *Nlrp3*^{-/-} mice (Method 2, 3 in Supplementary Figure 1a, b). In contrast, 25 % increase in myelin oligodendrocyte glycoprotein (MOG) peptide did not change EAE severity (Method 3 vs. 4 and 5 vs. 6 in Supplementary Figure 1a, b). Using the most aggressive EAE induction method (Method 6 in Supplementary Figure 1a, b), *Asc*^{-/-} and *Nlrp3*^{-/-} mice developed comparable disease severity to wild-type (WT) mice (Figure 1a), as well as similar numbers of total leukocytes, CD4⁺ T cells, and Th17 cells in spinal cords and brains (Fig. 1b, c; Supplementary Figure 1c). Importantly, EAE induced by the Method 6 completely abrogated the efficacy of IFNβ both in WT and *Nlrp3*^{-/-} mice (Figure 1d; Supplementary Figure 1d). Here, we tentatively termed the EAE subtype, which develops without the NLRP3 inflammasome and does not respond to IFNβ, as "Type-B EAE," in contrast to another EAE subtype, which is NLRP3 inflammasome-dependent and responds to IFNβ treatment (Figure 1d, right panel)(induced by the Method 1, and termed "Type-A EAE"). Type-B EAE mice could not clinically tell apart from Type-A EAE mice for the first 30 days in comparable body weights (Supplementary Figure 1e) and the lack of obvious difference in ataxia (Supplementary video 1). The results here also suggested that there are intermediate phenotypes between Type-A and Type-B EAE, which represent a continuum of the EAE subtypes.

Type-B EAE mice were characterized with low and basal levels of serum IL-1β (Figure 1e). Splenocytes from Type-B EAE mice showed significantly decreased ability to produce extracellular IL-1β, despite high expression of *Il1b* mRNA, and decrease in caspase-1 activity Supplementary Figure 1f-h). The results strongly suggest remarkably low levels of NLRP3 inflammasome activation in Type-B EAE. In contrast, high levels of serum IFNβ were observed in Type-B EAE mice (Figure 1f). As IFNβ suppresses NLRP3 inflammasome activity⁷, endogenous IFNβ may contribute to inhibit NLRP3 inflammasome activation in Type-B EAE mice.

Because Type-B EAE is induced with high dosages of adjuvant (*Mtb*), we sought to identify if acute infection converts the phenotype of mice, immunized with the Type-A EAE-induction, to develop Type-B EAE responses. Here, we intentionally used an agent, which is not *Mtb*, to test our hypothesis -- strong stimulation of innate immunity enhances Type-B EAE responses -- is not specific for the *Mtb* adjuvant. Murine gamma herpesvirus-68 (MHV-68), equivalent to Epstein-Barr virus (EBV) in humans, was used simply because of the relevance of EBV infection to MS¹¹. Type-A EAE induction accompanied with a high inoculum of MHV-68 made mice develop NLRP3 inflammasome-independent and IFNβ-

resistant EAE (Figure 1g). Taken together, it is possible that EAE is skewed towards Type-B by strong stimulation of innate immunity with high dosages of adjuvant or acute infection.

Distinct phenotypes between Type-A and Type-B EAE

Type-B EAE mice showed significantly higher numbers of various leukocytes than Type-A EAE mice on 17-day post immunization (dpi) in brains (peak time of disease)(Figure 1h, Supplementary Figure 1i, 1j). In contrast, Type-A EAE mice showed higher numbers of these cells than Type-B EAE mice in spinal cords (Figure 1h, Supplementary Figure 1i). Type-B EAE mice suffered mild demyelination in the spinal cord, whereas demyelination in Type-A EAE mice was severe (Figure 1i). Alternatively, Type-B EAE mice, but not Type-A EAE mice, suffered severe demyelination in the brain (proximal to choroid plexus, an entry zone of immune cells into the brain¹²) and in the optic nerve (Figure 1i, Supplementary Figure 1k). Magnetic resonance imaging (MRI) T2 FLAIR images showed hyperintensity, reflecting demyelination and cell density changes, in the external capsule and adjacent cortical regions in the brains of Type-B EAE mice at 18-dpi and to a lesser extent in the spinal cord (Figure 1j, Supplementary Figure 1l). Type-B EAE mice also showed thermal hyperalgesia at 9-dpi (before or around EAE onset), but mice with Type-A EAE did not (Supplementary Figure 1m). As shown in thermal hyperplasia, a pain syndrome is a manifestation of some MS patients. Although EAE scores are comparable between Type-A and Type-B EAE, mice with Type-B EAE showed distinct phenotypes, which are not reflected in the EAE score.

mLT on DCs plays a critical role in Type-B EAE development

To identify molecules involved in Type-B EAE, we compared gene expression between Type-A and Type-B EAE mice. PCR array analyses indicated high expression of *Lta* mRNAs in dendritic cells (DCs) isolated from draining lymph nodes (DLNs) of Type-B EAE mice (Supplementary Table 1). *Lta* encodes lymphotoxin α (LT α , also termed TNF β), which forms secreted homo-trimer or membrane-bound hetero-trimer with LT β (*i.e.*, mLT). Lymphotoxin (LT), at least, is known to be critical in the development of MS and EAE^{13, 14}, and was observed in demyelinated regions in the brain of some MS patient¹⁵, and serum¹⁶. Blockade of LT β R, an mLT receptor, ameliorates EAE induced by repetitive immunizations¹⁷, a condition that might approximate Type-B EAE. Although *Lta* mRNA is widely known to be expressed in lymphocytes, DCs and macrophages expressed enhanced levels of *Lta* mRNA and mLT in Type-B EAE (Figure 2a, b; Supplementary Figure 2a, b). Antigen was not required to induce mLT expression on DCs because a high dose of *Mtb* in CFA was sufficient (Supplementary Figure 2c), although the MOG antigen helped to further induce mLT expression in Type-B EAE (Figure 2b). These results suggest that strong stimulation of innate immunity with high dose of adjuvant alone is sufficient to induce mLT expression on DCs.

Induction of *Lta* mRNA levels in DCs was, at least in part, attributed to epigenetic alteration in the *Lta* gene locus. We found that the *Lta* promoter in DCs from Type-B EAE mice was hypomethylated, compared to naïve and Type-A EAE mice (Figure 2c; Supplementary Figure 2b). Importantly, LT β R signaling is essential for development of Type-B EAE, because an LT β R antagonist, LT β R-Fc, ameliorated Type-B EAE, but not Type-A EAE

(Figure 2d). We then hypothesized that recombinant LT (rLT; LT α 2 β 1), a soluble LT β R agonist, could “convert” the EAE phenotype from Type-A to the Type-B. With rLT treatment with Type-A EAE induction (Method 1 in Supplementary Figure 1a), *Nlrp3*^{-/-} mice developed severe EAE (Figure 2e) and WT mice lost responsiveness to IFN β treatment (Figure 2f). Moreover, rLT treatment increased the immune cell migration into the brain (Figure 2g) as observed in Type-B EAE mice (Figure 1h). Taken together, these findings strongly suggest mLT and LT β R are key factors for Type-B EAE development.

Type-B EAE and Th17 cell-mediated passive EAE

A previous report showed that IFN β treatment did not ameliorate passive EAE induced by Th17 cell adoptive transfer¹⁸. We sought a connection between Type-B EAE and Th17-mediated passive EAE. We found that rIL-17, but not rIFN γ , upregulated *Lta* expression in DCs (Figure 2h), suggesting that Th17 cells may induce Type-B EAE disease through upregulation of *Lta*. Indeed, LT β R blockade strongly ameliorated Th17-mediated passive EAE (Figure 2i). In addition, Th17 cells were potent enough to make *Asc*^{-/-} recipients develop severe EAE as well (Figure 2i). As we discuss in a later section, Type-A and Type-B EAE mice showed comparable numbers of Th17 cells in DLN. Thus, Type-B EAE responses do not appear to induce Th17 cells; rather, Th17 cell transfer induces Type-B EAE phenotypes through the mLT-LT β R axis.

CD4⁺ T cell gene expression profile in Type-B EAE

We next examined phenotypes of splenic CD4⁺ T cells in Type-B EAE. PCR array analyses indicated high expression of *Cxcr2* and *Cxcr1* mRNAs in CD4⁺ T cells isolated from splenocytes of Type-B EAE mice (Supplementary Table 2). To further address the broad changes of gene expression profile in CD4⁺ T cells, we performed high-throughput RNA-Seq analysis (Figure 3 and Supplementary Figure 3), and obtained distinct gene expression profile between Type-A EAE and Type-B EAE (Figure 3a). Six hundred sixty eight genes were upregulated more than 2-fold ($P < 0.05$) in CD4⁺ T cells from Type-B EAE mice compared to those from Type-A EAE mice, while 600 genes were downregulated more than 2-fold in CD4⁺ T cells from Type-B EAE mice. Several genes previously detected by PCR array, such as *Cxcr2* and *Cxcr1* (Supplementary Table 2), were consistently detected by RNA-Seq as highly expressed genes in Type-B EAE. Interestingly, highly expressed genes in Type-B EAE include those which encode pattern-recognition receptors and neuronal damage-related molecules (Figure 3c), suggesting enhanced inflammation and neuronal damages in Type-B EAE.

On CD4⁺ T cells in spleens from Type-B EAE mice, standard qPCR confirmed the results from qPCR array and RNA-Seq analyses on abundant expression of *Cxcr2*, *Cxcr1*, and *Ltbr* mRNA (Figure 3d). Expression of the genes in CD4⁺ T cells was induced by *ex vivo* rLT treatment (Figure 3e), suggesting the upregulation of the mRNA in Type-B EAE was mediated by enhanced LT β R stimulation.

Comparison between Type-A and Type-B EAE

We next sought to identify differences between the two EAE subtypes at the cellular and protein levels. At the cellular level in peripheral lymphoid organs, numbers of T cells (total

T, total CD4⁺ T, Th1, Th17, and Treg cells), DCs, macrophages, and neutrophils/polymorphonuclear leukocytes (PMNs) were similar between two EAE subtypes, except for total leukocytes and B cells in DLNs and spleens, on day 9 (Figure 4a). However, around the disease peak time, no cell types showed significant differences in their numbers (Supplementary Figure 4a). We also examined proportions of GM-CSF-producing Th1 and Th17 cells in the spleen at 9-dpi because they are encephalitogenic^{19, 20}. But no difference was found (Supplementary Figure 4b). Other Th17 cell subsets expressing IFN γ , GM-CSF, IL-22, or CD5L in the spinal cord at 17-dpi, also showed no difference in their population sizes between the two EAE subsets (Supplementary Figure 4d). These results suggested no marked alteration in leukocyte numbers in Type -B EAE.

We next focused on cell surface protein expression on leukocytes in secondary lymphoid organs. CXCR2 is known as a major chemokine receptor mainly on neutrophils. As expected, a majority of neutrophils expressed CXCR2 in both EAE subtypes, but mean fluorescent intensity (MFI) levels were significantly increased in Type-B EAE (Supplementary Figure 4e). In contrast, CD4⁺ T cells are not largely known to express CXCR2. Nevertheless, more than 10 % of CD4⁺ T cells from Type-B EAE mice expressed CXCR2 on their cell surface (Figure 4b, Supplementary Figure 4f). In addition, CXCR2⁺ macrophages were also more frequent and expressed higher levels of CXCR2 in Type-B EAE (Supplementary Figure 4e). Thus, the data suggested that Type-B EAE induces CXCR2 both in lymphoid and myeloid cells.

Gene expression in PBMCs from IFN β non-responder patients

We next compared gene expression of *CXCR2*, *CXCR1*, and *LTBR* between IFN β -responder and non-responder patients by using peripheral blood mononuclear cells (PBMCs), which are mixtures of lymphocytes, monocytes, and others. When relative expression levels to *VCAM1* were calculated (*VCAM1* is expressed in monocytes (Expression Atlas by EMBL-EBI) and is not differentially expressed between IFN β -responder and nonresponder RRMS patients²¹), the data showed that relative mRNA expression of *CXCR2*, *CXCR1*, and *LTBR* were significantly higher in IFN β -responders than nonresponders (Figure 4c). Here, the two-thirds of non-responders showed comparable gene expression levels to responders. It is possible that using total PBMCs evened out the changes in CD4⁺ T cells; thus, further analyses using purified CD4⁺ T cells are required to directly evaluate the gene expression. Coefficient of determination (R^2) values between relative expression levels of *CXCR1* and *LTBR* were particularly higher in non-responder than responder (Supplementary Figure 4g). Taken together, the data suggested that relative expression of *CXCR2*, *CXCR1* and *LTBR* might be used to distinguish IFN β -resistant MS.

Critical role of CXCR2 in Type-B EAE

As CD4⁺ T cells from Type-B EAE mice express high levels of CXCR2 (Figure 4b; Supplementary Figure 4e), the cells showed strong chemotaxis toward CXCL1, a ligand of CXCR2 (Figure 5a). Type-B EAE actually showed high levels of CXCL1 in serum, choroid plexus, and the spinal cord (Figure 5b, c; Supplementary Figure 5). The CXCL1 levels in serum and choroid plexus in Type-B EAE mice were reduced by blocking LT β R *in vivo*

(Figure 5d,e), suggesting mLT enhancing the CXCL1-CXCR2 axis in the development of Type-B EAE.

CXCR2 indeed was a key molecule specifically in Type-B EAE, because blockade of CXCR2 with SB225002 ameliorated Type-B EAE, but not Type-A EAE (Figure 5f). We confirmed the involvement of CXCR2 on T cells *in vivo* by using *Cxcr2^{fl/fl}LckCre⁺* (CXCR2 cKO) mice, which lack CXCR2 in T cells. The lack of CXCR2 in T cells did not alter disease score in Type-A EAE. However, although CXCR2 deficiency in T cells eventually allowed mice to develop severe Type-B EAE, it significantly slowed the Type-B EAE onset (Figure 5g). SB225002-treated mice and CXCR2 cKO mice showed mild demyelination in the spinal cord at 17-dpi (Figure 5h). Taken together, we demonstrated the critical role of T cell CXCR2 in Type-B EAE.

Virus infection enhanced the Type-B EAE phenotype

We have shown that a high inoculum of MHV-68 made mice, despite of Type-A induction, develop NLRP3 inflammasome-independent and IFN β -resistant EAE (Figure 1g). MHV68 infection also increased CXCR2⁺CD4⁺ T cells together with mLT-expressing DCs (Figure 5i). Furthermore, MHV68 infection converted Type-A-induced mice to develop Type-B EAE responses, such as reduced serum IL-1 β levels and induced CXCL1 levels (Figure 5j), allowing infected mice, despite of Type-A EAE induction, to respond treatments that block LT β R or CXCR2 (Figure 5k). These results suggest strong stimulation of innate immunity triggers LT β R-CXCR2 axis to induce the Type-B EAE phenotype.

Minimum remission with neuronal damage in Type-B EAE mice

Type-B EAE mice showed persistent EAE severity with little remission (Figure 6a). To investigate the long-term disease severity, we focused the spinal cord rather than the brain, because the spinal cord is responsible for overt motor disability in EAE. Regardless of significantly severe demyelination in spinal cord (Figure 6b), leukocyte infiltration was not clearly observed in the spinal cords in Type-B EAE mice (Supplementary Figure 6a) at a later stage of EAE on 60~70-dpi. Then, rather than sustained inflammation triggered by infiltrated leukocytes, we considered the possibility of poor remyelination to explain the sustained EAE phenotype. However, Type-B EAE mice at least successfully expressed insulin-like growth factor (IGF)-1, a critical molecule in remyelination^{22, 23} (Supplementary Figure 6b).

We next evaluated morphology of neurons in spinal cord sections from EAE mice, because a previous study demonstrated the loss of neurites in some MS patients²⁴. We performed Bielschowsky neuronal staining, and found that Type-B EAE mice showed fainter staining particularly in outer areas of the white matter, which may include the descending tracts (Supplementary Figure 6c, Arrows). Furthermore, Golgi silver staining, which stains random subsets of neurons, revealed that Type-B EAE mice at 70-dpi showed low-density, transected neurites in the spinal ventral horn containing motor neurons (Figure 6c). Stereological analysis confirmed the significant reduction of α -motor neurons and interneurons surrounding α -motor neurons in the spinal ventral horn of Type-B EAE mice (Figure 6d). In contrast, Type-A EAE mice showed similar neuronal morphology and numbers of α -motor

neurons to naïve mice (Figure 6c, d; Supplementary Figure 6d). At an earlier stage of EAE (22-dpi), the difference between Type-A and Type-B EAE Golgi staining was not identified (Supplemental Figure 6e). These results suggested that the minimal remission in Type-B EAE may be attributed to irreversible loss of axons in Type-B EAE.

Type-B EAE CD4⁺ T cells induce neuronal retraction by Sema6B

To further investigate the altered neuronal morphology in Type-B EAE mice, we examined primary hippocampal neurons co-cultured with CD4⁺ T cells from EAE mice. In neuron-T cell co-culture, significant suppression of neurite outgrowth and reduction in the number of axon, dendrites, and branches were observed when CD4⁺ T cells were from Type-B EAE mice. However, the phenomenon was not seen with T cells from Type-A EAE mice (Figure 7a). Quantitative analyses confirmed decreased lengths of neurites and numbers of axon/dendrite branches with CD4⁺ T cells from Type-B EAE mice (Figure 7b, c).

To identify molecules responsible for transected neurites specific for Type-B EAE, we examined expression levels of axon guidance molecules in the semaphorin and ephrin families. Among several molecules, which potentially inhibit neurite outgrowth, semaphorin 6B (Sema6B; a class 6 transmembrane semaphoring)²⁵ gene expression was particularly high in CD4⁺ T cells from Type-B EAE mice (Figure 7d). Knocking-down *Sema6b* mRNA by shRNA (62 % reduction of mRNA, Supplementary Figure 7) in CD4⁺ T cells from Type-B EAE mice almost completely rescued neurite outgrowth (Figure 7e, f). Importantly, rLT treatment induced *Sema6b* mRNA expression in CD4⁺ T cells isolated from Type-A EAE mice (Figure 7g). rLT-treated CD4⁺ T cells potentially shortened neurite lengths and numbers of neurites in *ex vivo* co-culture (Figure 7h). In sum, these results suggested that Sema6B upregulation by the LTβR signaling in CD4⁺ T cells enhances neurite retraction in Type-B EAE mice.

DISCUSSION

In this study, we demonstrated that strong activation of the innate immune system substantially impacts the development of EAE and disease phenotype, *i.e.*, high dosages of adjuvant (heat-killed Mycobacteria; *Mtb*) were sufficient to induce distinct subtype of EAE (Summarized in Supplementary Figure 8). This simple method enabled us to study the heterogeneity of EAE without using confounding factors such as; special reagents, genomic mutations, mRNA knock-down, and mouse strains other than commonly used C57BL/6. As an environmental cue of “strong activation of the innate immune system,” we demonstrated that acute virus infection could mimic the effect of increased *Mtb* and converts Type-A EAE to Type-B EAE, leading to the failure of IFNβ treatment. The result suggests that intensity of infections could modulate autoimmune responses and possibly alters treatment options, at least in part, from the mechanism we demonstrate in this study.

Type-B EAE is distinct from Type-A EAE in: (1) increased recruitment of inflammatory cells in the brain, (2) prolonged disease with more neuronal damage, and (3) gene and protein expression profiles. Yet, Type-B EAE pathology did not alter composition of major leukocyte subpopulations. Based on the gene expression patterns between two EAE subtypes, development of Type-B EAE may inhibit development of Type-A EAE. For

example, high levels of endogenous IFN β in Type-B EAE condition are considered to suppress NLRP3 inflammasome activity⁷, which is required for Type-A EAE. Importantly, Type-B EAE development depends on the mLT-LT β R axis. Indeed, Type-B EAE cannot be treated by IFN β , but ameliorated by an LT β R antagonist. Furthermore, rLT treatment switches Type-A EAE to Type-B EAE. We do not call Type-B EAE in this study as “atypical EAE”, which was previously reported by a number of laboratories because Type-B EAE mice do not show phenotypes of “atypical EAE” such as severe gait ataxia, hemiparesis, and cellular infiltration in the cerebellum^{26–29}. It is of note that Liu et al. also demonstrated that CXCR2 blockade ameliorated atypical EAE, and the CXCR2 blockade mechanism of atypical EAE was shown to work through neutrophils²⁷. Alternatively, our data suggested blocking CXCR2 on CD4⁺ T cells is critical to ameliorate Type-B EAE.

We have shown that rIL-17 induces *Lta* expression (*Lta* is highly expressed in Type-B EAE). In addition, LT β R blockade ameliorates Th17-mediated EAE (and Type-B EAE). These results suggest that Th17-mediated EAE and Type-B EAE share some common pathology. Indeed, previous reports showed that Th17-mediated EAE was characterized with induced neuronal damage³⁰ and resistance to IFN β treatment¹⁸. We also demonstrated that Type-B EAE is characterized with neuronal damage and resistance to IFN β treatment.

Our results suggested that mLT expressed on DCs increases CXCR2 expression on CD4⁺ T cells, neutrophils, and macrophages to induce Type-B EAE. In addition, mLT-mediated induction of CXCL1, as well as its receptor CXCR2, was shown to be critical for Type-B EAE induction. Although CXCR2 is widely known as a neutrophil receptor, we found that CD4⁺ T cells induce expression of CXCR2 in Type-B EAE; and CXCR2 on T cells are essential for early phase Type-B EAE development. CXCR2 on CD4⁺ T cells was also reported in other conditions, such as aging³¹, Alzheimer’s disease³², and tuberculosis³³. Here, we found that rLT treatment induces CXCR2 expression on CD4⁺ T cells *in vivo*, as well as serum CXCL1. A previous study showed that LT β R signaling is required for upregulation of CXCL1 expression in intestinal epithelial cells for neutrophil recruitment to the bacterial infection site³⁴. The interplay between LT β R and the CXCL1-CXCR2 axis appears to be critical to induce inflammation and is involved in the pathogenesis of Type-B EAE.

We demonstrated that, by using PBMCs from RRMS patients, IFN β non-responder showed elevated relative expression of *CXCR2*, *CXCR1*, and *LTBR* than IFN β -responders. Although only PBMCs were available to this study, further analyses using purified CD4⁺ T cells from patients will be required to delineate pathogenic mechanisms involving CXCR1/2 and LT β R in MS, and to evaluate whether Type-B EAE recapitulates phenotype of IFN β -resistant MS.

Type-A and Type-B EAE have distinct phenotypes in the CNS. In particular, Type-B EAE shows minimal remission because of neuronal damage, which is irreversible and reminiscent of progressive MS that shows no disease remission with neuronal damage^{35, 36}. Regarding neuronal damage in Type-B EAE, we demonstrated that Sema6B generated by CD4⁺ T cells causes neurite retraction. Previous reports demonstrated that Sema6B, detected by its receptors (plexin-A2 and plexin-A4), induces neuronal growth cone collapse and

repulsion^{25, 37–39}. The finding in the previous reports may share its mechanism to Sema6B-dependent neurite retraction in Type-B EAE. Although there is no report on Sema 6B in MS, other semaphorins were reported in the light of MS. The report demonstrated that Sema 3A and 3F transcripts are detected around and within demyelinating white matter lesions in MS patients⁴⁰.

Our RNA-Seq analysis identified genes highly expressed in CD4⁺ T cells from Type-B EAE mice. Some genes shown in Figure 3c are considered to be involved in neuronal damage. In particular, phospholipase A2, encoded by *Pla2g4a* and *Pla3g7* genes, induces neuronal damage as a secreted form^{41, 42}. MGST1, encoded by *Mgst1*, also damages neurons by activating prostaglandin E synthase⁴³. *Alox5ap* gene encodes the arachidonate 5-lipoxygenase (ALOX5) activating protein, which facilitates leukotriene biosynthesis: ALOX5 and leukotriene are detected in MS lesions and cerebrospinal fluid from MS patients, respectively^{44, 45}, and contribute to axonal damage⁴⁶. The RNA-Seq analysis did not pick up *Sema6b*, because its expression levels were not abundant enough for drawing a conclusion from the RNA-Seq approach. Yet, induction of *Sema6b* mRNA was detected with increased expression in CD4⁺ T cells from Type-B EAE mice by standard qPCR.

Here, we report that strong activation of innate immunity makes the EAE pathological mechanism bypass the NLRP3 inflammasome; and the EAE subtype developed without the NLRP3 inflammasome (*i.e.*, Type-B EAE) showed distinct mechanisms in disease development and responses to drug treatment. Although further studies are required to answer whether the Type-A/Type-B EAE spectrum recapitulates the heterogeneity in MS at least to some extent, elucidating mechanisms to generate the heterogeneity in EAE may provide new molecular insights in developing prognosis and treatments of MS as a heterogeneous disease.

Online Methods

Animals

Healthy male mice of the C57BL/6 background of 6–8 weeks old were randomly selected and used in this study. The *Asc*^{-/-} and *Nlrp3*^{-/-} mice were gifts from Genentech under material transfer agreement (MTA), and were rederived in our facility. *Cxcr2*^{fl/fl} mice were a gift from Dr. Richard M. Ransohoff (Cleveland Clinic)⁴⁷. C57BL/6 and *Lck-Cre* transgenic mice were purchased from Jackson Laboratories. All the mice were kept group-housed (2–5 mice per cage) in a specific pathogen free facility with 12h each of a light-dark cycle. One cage housed up to five mice. Mice in one experimental group were collected from at least 2 litters. This study was approved by the Duke University Institutional Animal Care and Use Committee.

Reagents

SB225002, a specific CXCR2 inhibitor, was purchased from Tocris. LTβR-Fc (PRO154527) is a gift from Genentech under MTA. Antibodies against LT (ab100844), CXCR2 (129101), and CXCL1 (LS-B2513) were purchased from Abcam, BioLegend, and Life Span Bioscience, respectively. The rIFNβ used in EAE treatment was human rIFNβ-1b

(Betaseron, Bayer). rLT (rLT α 2 β 1; 1008-LY-010/CF) was purchased from R & D systems. Mouse rCXCL1 (573702), rIL-17 (576002) and rIFN γ (575306) were purchased from BioLegend. MOG₃₅₋₅₅ peptide was synthesized by United Peptides. Enzyme-linked immunosorbent assay (ELISA) kits for the detection of IL-1 β and CXCL1 were purchased from BD PharMingen, and Promocell, respectively.

Induction of active EAE

Type-A EAE was induced as previously described⁴⁸. MOG₃₅₋₅₅ peptide was emulsified with CFA (including *Mtb*), and subcutaneously injected in the flanks of mice on day 0 for one-time immunization, or day 0 and 7 for two-time immunization. Pertussis toxin (PTx; 200 ng/mouse) was administered on day 0 and 2, if the MOG immunization was performed once on day 0. If the immunization was performed twice on day 0 and 7, 200 ng/mouse PTx was administered on day 0, 2, and 7. EAE was induced by 6 different methods. Method 1: *Mtb* 200 μ g, MOG peptide 100 μ g, 1 time of immunization, Method 2: *Mtb* 200 μ g, MOG peptide 100 μ g, 2 time of immunization, Method 3: *Mtb* 400 μ g, MOG 100 μ g, 1 time of immunization, Method 4: *Mtb* 400 μ g, MOG peptide 125 μ g, 1 time of immunization, Method 5: *Mtb* 400 μ g, MOG peptide 100 μ g, 2 time of immunization, and Method 6: *Mtb* 400 μ g, MOG peptide 125 μ g, 2 time of immunization. EAE scores were assessed daily for clinical signs of EAE in a blinded fashion as previously described²⁴. EAE severity was also evaluated as an area under the curve (AUC) from time course experiments. EAE score was evaluated as; 0.5, partial tail limpness, 1, tail limpness, 1.5, reversible impaired righting reflex, 2, impaired righting reflex, 2.5, one hind limb paralysis, 3, both hind limb paralysis, 3.5, both hind and one fore limb paralysis, 4, hind and fore limb paralysis, 5, death. We provided water gel and powder feed when score 2 to avoid body weight reduction because of no reaching to feed and water. Disease score analysis and video-recording was performed in the middle of the day during the light cycle.

Induction of passive EAE

To polarize Th17 cells, total splenocytes were obtained from naïve MOG-specific 2D2 CD4⁺ TCR Tg mice, and cultured with MOG₃₅₋₅₅ peptide (3 μ g/ml), IL-6 (20 ng/ml), TGF β (4 ng/ml), and IL-23 (50 ng/ml) for 6 days. Cells (3×10^7) were transferred *i.v.* into sublethally irradiated (450 rad) B6 and *Asc*^{-/-} mice.

Pharmaceutical treatment of mice with EAE

IFN β (3×10^4 unit/mouse) were *i.p.* injected every other day from day 0 to 8 as previously performed²⁴. rLT (rLT α 2 β 1)(1008-LY-010/CF, R&D; 10 μ g/kg mouse) was *i.p.* administered every day from day 0 to 9. CXCR2 inhibitor (SB225002, Tocris; 0.1 mg/kg mouse) was *i.p.* injected every day from day 0 to day 20. LT β R-Fc (PRO154527, Genentech)(150 ng/mouse) was *i.p.* injected every other day from day 0.

MHV68 infection

MHV68 was purchased from ATCC Cell Lines (VR-1465). MHV68 strains were amplified in BALB/3T12-3 cells (ATCC, CCL-164TM), and virus-infected cells were treated with three freeze-thaw cycles, and then supernatant was isolated. Titers of purified virus were

determined using the median tissue culture infective dose (TCID₅₀) method, and convert TCID₅₀ to plaque forming units (PFU). MHV68 (10⁵ pfu/mouse) was inoculated through *i. v.* at the time of Type-A EAE immunization.

Confocal microscopy

Transverse sections (30 μm) of brains and spinal cords were stained with CXCL1 antibody (Life Span Bioscience) and DAPI (Invitrogen) then analyzed with Zeiss LSM750 laser scanning confocal microscope through the Plan-Apochromat 63×/1.40 oil DIC M27 (*n*=4). Images were captured with AxioCam (Zeiss) and analyzed by ZEN software (Zeiss).

Western blot analysis

To detect active caspase-1, we analyzed culture supernatant of spleen (5×10⁶ cells) isolated from EAE at 9-dpi by Western blotting with antibody against active caspase-1 (1:500), which was gift from Genentech. Horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000, BD Pharmingen) was used to detect signals, which were visualized by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).

RNA and cDNA preparation for standard qPCR and PCR array analyses

For standard qPCR and PCR array analysis, splenic CD4⁺ T cells and CD11c⁺MHCII⁺ cells (as DCs from DLNs) were isolated by FACS-sorting on 9-dpi. Total RNA was extracted from cells with RNeasy Kit (Qiagen). cDNA synthesis was performed with qScript cDNA SuperMix (Quanta). qPCR analysis was performed with KAPA-SYBR-FAST (KAPA Bio Systems) with an initial denaturing step at 95°C for 3 min, followed by 35 cycles of a denaturation step at 94°C for 3 s and an annealing and extension step at 60°C for 30 s. The relative amounts of qPCR products were determined with the *Ct* method to compare the relative expression of target genes and housekeeping genes. The expression of the gene encoding β-actin was used as an internal control⁴⁹. Primer sequences were indicated in Supplementary Table 3. PCR array was performed by using Chemokines & Receptors PCR Array (PAMM-022Z, Qiagen) and Cytokines & Chemokines PCR Array (PAMM-150Z, Qiagen) with CD4⁺ T cells DCs, respectively.

RNA-seq analysis

CD4⁺ T cells were purified by FACS-sorting from spleens of two mice at 9-dpi. Total RNA was extracted from cells with RNeasy Kit (Qiagen). Stranded mRNA libraries were made with the Illumina TruSeq Stranded mRNA kit (catalog number RS-122-2101). The quality of RNA libraries was checked by running them on a 2100 Bioanalyzer instrument (Agilent), pooled and sequenced on 2 lanes of Illumina HiSeq 50bp SR. RNA-seq data was processed using the TrimGalore toolkit (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore), which employs Cutadapt⁵⁰ to trim low quality bases and Illumina sequencing adapters from the 3' end of the reads. Only pairs where both reads were 20-nt or longer were kept for further analysis. Reads were mapped to the NCBI38r73 version of the mouse genome and transcriptome⁵¹ using the STAR RNA-seq alignment tool⁵². Reads were kept for subsequent analysis if they mapped to a single genomic location. Gene counts were compiled using the HTSeq tool (<http://www-huber.embl.de/users/anders/HTSeq/>). Only

genes that had at least 10 reads in any given library were used in subsequent analysis. Normalization and differential expression was carried out using the EdgeR⁵³ and Bioconductor⁵⁴ package with the R statistical programming environment (www.r-project.org). The exact test method⁵⁵ was used to identify differentially expressed genes between the different conditions. Enriched pathways were determined by GSEA⁵⁶.

RRMS patient's information and qPCR analysis

PBMC samples from RRMS patients were obtained from the MURDOCK study cohorts (IRB# Pro00023791) with the informed consent (<http://www.murdock-study.com/>). Each participant self-reported their drug history, which includes the drug, start and end dates, and comments. Comments on discontinued drugs typically include the reason for discontinuation, and we selected IFN β non-responders as those that self-reported stopping an interferon drug due to it not working. Relapses and more lesions via MRI were often cited, and some referred to positive neutralizing antibody results, but sometimes they just reported that it was not working without further description. IFN β responders were currently taking an interferon drug with no reports of disease progression, and we weighted selection to those that explicitly reported that the drug was working for them and that they had not had relapses or developed more lesions while on it. We excluded patients who used drugs other than IFN β . Three male patients are included in each group. We used samples from 18 patients (15 female and 3 male) per group. Ages of patients vary from 23 years old to 64 years old in the responder group (the mean of 47.0 years old, SD of 11.429; the age of one patient was unknown), and from 26 to 68 years old in the non-responder group (the mean of 47.8 years old, SD of 10.837). RNA from samples responder and non-responder groups were quantified via Ribogreen, normalized and converted to cDNA using the SuperScript® VILO™ cDNA Synthesis Kit. Gene expression assays utilized the TaqMan® Gene Expression protocol and run on the ViiA™ 7 Real-Time PCR System.

DNA methylation assay

DCs were FACS-sorted as CD11c⁺CD11b⁻ from DLNs of naïve and EAE mice at 9-dpi. Genomic DNA was obtained with the GenElute™ Mammalian Genomic DNA Miniprep kit (Sigma). Bisulfite conversion was performed with the MethylDetector kit (Active Motif), and the *Lta* promoter (between -363-nt and +65-nt from the transcription start site) was cloned into the pCR4-TOPO-TA vector (Life Technologies) and transformed into *E. coli*. Methylation status was evaluated by sequencing 17–22 clones per group. Percentages of unmethylated CpG in all the tested CpG sites were calculated.

Analyzing demyelination

For Luxol fast blue (LFB) staining, transverse sections (5 μ m) of spinal cord and the brain from mice at 17-dpi were stained. MRI analysis was performed with mice with either Type-A or Type-B EAE at 18-dpi. As a procedure for MRI, 10% buffered formalin-perfused mouse brains were kept within the cranium to prevent any potential damage to the brain caused by surgical removal. All images were acquired using a 9.4 T (400 MHz) 89-mm vertical bore Oxford magnet with shielded coil providing gradients of 2200 mT/m. The system is controlled by the Agilent imaging console. The specimens were scanned using a 2D fluid attenuated inversion recovery (FLAIR) sequence with the following parameters:

FOV = 22×11 mm², matrix = 256×128, 0.5-mm slice thickness with zero gap, TR/TI/TE = 5000/925/30.8 ms, echo train length (ETL) = 8, bandwidth = 100 kHz and 12 averages.

Neuronal staining and motor neuron analysis by stereology

Neuronal staining was performed by Golgi's silver staining with the FD Rapid Golgi staining kit (FD Neurotechnologies, Inc.) and Bielschowsky staining with Hito Bielschowsky OptimStain™ Kit (Hito Biotec) according to manufacturer's protocol. For stereological analysis, 4% paraformaldehyde-fixed spinal cords were removed from EAE mice at 70 dpi. Tissue sections (30 μm) were analyzed by stereology using Stereo Investigator v11 (MicroBrightfield, Williston, VT) using a Zeiss AxioImager M2 microscope. Contours were drawn around the ventral horn with a 5× objective and neuronal counting was completed using a 63×/1.40 oil objective (Zeiss). Beginning at L6 and moving caudally, we sampled 10 lumbar spinal sections at a section interval of 5. Using the resample oversample tool in Stereo Investigator, we first determined that at a section interval of 5, a systematic random sampling (SRS) grid size of 164×90 would allow precise cell estimates in the ventral horn of the lumbar region. The mounted thickness was 22 μm after tissue shrinkage and we used 2 μm guard zones. The dissector height was 18 μm and the counting frame size was 75×75 μm. Stereology parameters were indicated in Supplementary Table 4. The total numbers of bilateral Nissl-stained ventral horn neurons were counted stereologically with the Stereo Investigator software by using an optical fractionator. α-motor neurons were defined by having a maximal diameter greater than 30 μm. The average number of α-motor neurons (>30 μm) was 162. The average number of total Nissl-stained neurons counted per animal was 337. Our analysis produced a CE (Gundersen, m=1) of 0.078.

CD4⁺ T cell-neuron co-culture, and neurite length measurement

Primary neurons were obtained from the hippocampus of P2 mice, as previously described⁵⁷. After papain treatment to hippocampus tissue, 1×10⁵ cells were cultured for 8 days. Splenic CD4⁺ T cells were isolated with CD4 microbeads (Myltenyi) and cultured with neuron for 24h. Neuron and nuclear staining were performed with MAP2 and DAPI, respectively. Neurite lengths and numbers of total axons, dendrites and branches were analyzed with the NeuroLucida software (MBF bioscience) using at least 18 neurons per condition.

Hot-plate test

To evaluate thermal sensitivity, a "hot plate test"⁵⁸ (52 °C and 40-sec cut-off) was used for mice at 9-dpi during the light cycle (*i.e.*, day time)

Chemotaxis assay

As previously described⁸, splenic CD4⁺ T cells (1×10⁶ cells/well) obtained from naïve mice or EAE mice at 9-dpi were plated in upper chambers of Transwell (5 μm pore, Corning Costar). rCXCL1 was added to lower chambers, and cells were incubated for 3 hr at 37 °C. Numbers of migrated cell were counted, and the data are displayed after subtracting cell numbers in lower chambers in untreated group (as control).

Statistical analysis

Statistical analysis in all results, except for human sample analysis and for motor neuron stereology analysis, was evaluated with two-tailed unpaired Student's *t* tests and *t*-values. The criterion of significance was set as $P < 0.05$. Statistical analysis for human samples was carried out with the *Mann-Whitney U test*. Differences among means in motor neuron stereology analysis were analyzed by one-way ANOVA followed by Bonferroni post hoc testing for pairwise comparison unless otherwise stated. Animals were randomly used for experiments under the criteria aforementioned in the section of "Animals." All behavior experiments were performed in a blinded fashion. No animals or data points were excluded. Quantifications were performed from at least two experimental groups in a blinded fashion. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those generally employed in the field. Data distribution was assumed to be normal, but this was not formally tested. Blinding and randomization was performed in all experiments.

A supplementary methods checklist is available

Data Availability

The RNA-seq data have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE85946. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank A. Uezu for his help in primary hippocampal neuron culture and Golgi staining, S. McKinnon for his help in isolating optic nerves, and M. Luftig for MHV68 experiments, M. Skeen for discussions on IFN β treatments on MS patients. We are also grateful to S. Cote, S. Arvai, and all participants in the MURDOCK Study Community Registry and Biorepository and the MURDOCK Multiple Sclerosis Cohort Study. We thank MURDOCK Study leadership and staff, including K. Newby (PI), for providing samples and support. This study was funded by the National Multiple Sclerosis Society (RG4536 to M.L.S.; RG4723 to C.L.) and NIH (R01MH096979 and P41EB015897 to C.L.).

References

1. Haines JD, Inglese M, Casaccia P. Axonal damage in multiple sclerosis. *Mt Sinai J Med*. 2011; 78:231–243. [PubMed: 21425267]
2. Rio J, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. *Ann Neurol*. 2006; 59:344–352. [PubMed: 16437558]
3. Rivers TM, Sprunt DH, Berry GP. Observations on Attempts to Produce Acute Disseminated Encephalomyelitis in Monkeys. *J Exp Med*. 1933; 58:39–53. [PubMed: 19870180]
4. Arnon R, Sela M. Immunomodulation by the copolymer glatiramer acetate. *J Mol Recognit*. 2003; 16:412–421. [PubMed: 14732933]
5. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. *J Cell Biol*. 2012; 199:413–416. [PubMed: 23109666]
6. Simmons SB, Pierson ER, Lee SY, Goverman JM. Modeling the heterogeneity of multiple sclerosis in animals. *Trends Immunol*. 2013; 34:410–422. [PubMed: 23707039]

7. Inoue M, et al. Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. *Sci Signal*. 2012; 5:ra38. [PubMed: 22623753]
8. Inoue M, Williams KL, Gunn MD, Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A*. 2012; 109:10480–10485. [PubMed: 22699511]
9. Gris D, et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. *J Immunol*. 2010; 185:974–981. [PubMed: 20574004]
10. Shaw PJ, et al. Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. *J Immunol*. 2010; 184:4610–4614. [PubMed: 20368281]
11. Smyk DS, Alexander AK, Walker M. Acute disseminated encephalomyelitis progressing to multiple sclerosis: Are infectious triggers involved? *Immunol Res*. 2014
12. Meeker RB, Williams K, Killebrew DA, Hudson LC. Cell trafficking through the choroid plexus. *Cell Adh Migr*. 2012; 6:390–396. [PubMed: 22902764]
13. Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. *J Exp Med*. 1997; 185:2039–2041. [PubMed: 9221283]
14. Lock C, Oksenberg J, Steinman L. The role of TNFalpha and lymphotoxin in demyelinating disease. *Ann Rheum Dis*. 1999; 58(Suppl 1):I121–128. [PubMed: 10577988]
15. Woodroffe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. *Cytokine*. 1993; 5:583–588. [PubMed: 8186370]
16. Kraus J, et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. *Acta Neurol Scand*. 2002; 105:300–308. [PubMed: 11939943]
17. Columba-Cabezas S, et al. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein. *J Neuroimmunol*. 2006; 179:76–86. [PubMed: 16870269]
18. Axtell RC, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. *Nat Med*. 2010; 16:406–412. [PubMed: 20348925]
19. Codarri L, et al. RORgammaT drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. *Nat Immunol*. 2011; 12:560–567. [PubMed: 21516112]
20. Wang C, et al. CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity. *Cell*. 2015; 163:1413–1427. [PubMed: 26607793]
21. Bustamante MF, Nurtdinov RN, Rio J, Montalban X, Comabella M. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. *PLoS One*. 2013; 8:e60994. [PubMed: 23637780]
22. Roth GA, Spada V, Hamill K, Bornstein MB. Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue. *Brain Res Dev Brain Res*. 1995; 88:102–108. [PubMed: 7493400]
23. McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor I/somatostatin C: a potent inducer of oligodendrocyte development. *Proc Natl Acad Sci U S A*. 1986; 83:822–826. [PubMed: 3511475]
24. Magliozzi R, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain*. 2007; 130:1089–1104. [PubMed: 17438020]
25. Tawarayama H, Yoshida Y, Suto F, Mitchell KJ, Fujisawa H. Roles of semaphorin-6B and plexin-A2 in lamina-restricted projection of hippocampal mossy fibers. *J Neurosci*. 2010; 30:7049–7060. [PubMed: 20484647]
26. Rothhammer V, et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. *J Exp Med*. 2011; 208:2465–2476. [PubMed: 22025301]
27. Liu Y, et al. Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype. *J Immunol*. 2015; 195:841–852. [PubMed: 26085687]

28. Qin H, et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. *Proc Natl Acad Sci U S A*. 2012; 109:5004–5009. [PubMed: 22411837]
29. Lukens JR, et al. The NLRP12 Sensor Negatively Regulates Autoinflammatory Disease by Modulating Interleukin-4 Production in T Cells. *Immunity*. 2015; 42:654–664. [PubMed: 25888258]
30. Siffrin V, et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. *Immunity*. 2010; 33:424–436. [PubMed: 20870176]
31. Mo R, et al. T cell chemokine receptor expression in aging. *J Immunol*. 2003; 170:895–904. [PubMed: 12517955]
32. Liu YJ, et al. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. *Neurobiol Aging*. 2010; 31:175–188. [PubMed: 18462836]
33. Pokkali S, Das SD, RL. Expression of CXC and CC type of chemokines and its receptors in tuberculous and non-tuberculous effusions. *Cytokine*. 2008; 41:307–314. [PubMed: 18226915]
34. Wang Y, et al. Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. *Immunity*. 2010; 32:403–413. [PubMed: 20226692]
35. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. *Brain*. 1994; 117(Pt 4):759–765. [PubMed: 7922463]
36. Thompson AJ, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. *Ann Neurol*. 1991; 29:53–62. [PubMed: 1996879]
37. Suto F, et al. Plexin-a4 mediates axon-repulsive activities of both secreted and transmembrane semaphorins and plays roles in nerve fiber guidance. *J Neurosci*. 2005; 25:3628–3637. [PubMed: 15814794]
38. Zhuang B, Su YS, Sockanathan S. FARP1 promotes the dendritic growth of spinal motor neuron subtypes through transmembrane Semaphorin6A and PlexinA4 signaling. *Neuron*. 2009; 61:359–372. [PubMed: 19217374]
39. Suto F, et al. Interactions between plexin-A2, plexin-A4, and semaphorin 6A control lamina-restricted projection of hippocampal mossy fibers. *Neuron*. 2007; 53:535–547. [PubMed: 17296555]
40. Williams A, et al. Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? *Brain*. 2007; 130:2554–2565. [PubMed: 17855378]
41. Liu NK, et al. Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. *Ann Neurol*. 2014; 75:644–658. [PubMed: 24623140]
42. Kolko M, Rodriguez de Turco EB, Diemer NH, Bazan NG. Neuronal damage by secretory phospholipase A2: modulation by cytosolic phospholipase A2, platelet-activating factor, and cyclooxygenase-2 in neuronal cells in culture. *Neurosci Lett*. 2003; 338:164–168. [PubMed: 12566178]
43. Takemiya T, et al. Endothelial microsomal prostaglandin E synthase-1 facilitates neurotoxicity by elevating astrocytic Ca²⁺ levels. *Neurochem Int*. 2011; 58:489–496. [PubMed: 21219953]
44. Whitney LW, Ludwin SK, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. *J Neuroimmunol*. 2001; 121:40–48. [PubMed: 11730938]
45. Neu I, Mallinger J, Wildfeuer A, Mehlber L. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. *Acta Neurol Scand*. 1992; 86:586–587. [PubMed: 1336293]
46. Yoshikawa K, Palumbo S, Toscano CD, Bosetti F. Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. *Prostaglandins Leukot Essent Fatty Acids*. 2011; 85:43–52. [PubMed: 21555210]
47. Liu L, et al. Functional defect of peripheral neutrophils in mice with induced deletion of CXCR2. *Genesis*. 2013; 51:587–595. [PubMed: 23650205]

48. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. *Immunity*. 2008; 29:68–78. [PubMed: 18619869]
49. Shinohara ML, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. *Nat Immunol*. 2006; 7:498–506. [PubMed: 16604075]
50. Lopez-Alvarez J, et al. Balloon dilation of an imperforate cor triatriatum dexter in a Golden Retriever with concurrent double-chambered right ventricle and subsequent evaluation by cardiac magnetic resonance imaging. *J Vet Cardiol*. 2011; 13:211–218. [PubMed: 21835710]
51. Kersey PJ, et al. Ensembl Genomes: an integrative resource for genome-scale data from non-vertebrate species. *Nucleic Acids Res*. 2012; 40:D91–97. [PubMed: 22067447]
52. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29:15–21. [PubMed: 23104886]
53. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics*. 2010; 26:139–140. [PubMed: 19910308]
54. Gentleman RC, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*. 2004; 5:R80. [PubMed: 15461798]
55. Robinson MD, Smyth GK. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. *Biostatistics*. 2008; 9:321–332. [PubMed: 17728317]
56. Mootha VK, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*. 2003; 34:267–273. [PubMed: 12808457]
57. Banker G, Goslin K. Developments in neuronal cell culture. *Nature*. 1988; 336:185–186. [PubMed: 3185736]
58. Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. *J Pharmacol Exp Ther*. 1953; 107:385–393. [PubMed: 13035677]




Figure 1. Type-B EAE develops independent of the NLRP3 inflammasome and is resistant to IFN β treatment

(a) EAE scores after Type-B EAE induction ($n=5$). AUC was calculated from Type-A and Type-B EAE data between day 0–23 dpi. Type-A EAE: $P_{(WT\ vs\ Nlrp3^{-/-})} < 0.0001$, $t(8)=12.78$, $P_{(WT\ vs\ Asc^{-/-})} < 0.0001$, $t(8)=10.57$. Type-B EAE: $P_{(WT\ vs\ Nlrp3^{-/-})}=0.7236$, $t(8)=0.3634$, $P_{(WT\ vs\ Asc^{-/-})}=0.6869$, $t(8)=0.4181$. (b, c) Numbers of total CD4 $^{+}$ T cells (b), and Th17 cells (c) in the brains and spinal cords of mice with Type-B EAE at 17-dpi. $n=4$. CD4 $^{+}$ T in Brain: $P_{(WT\ vs\ Nlrp3^{-/-})}=0.4507$, $t(6)=0.8065$, $P_{(WT\ vs\ Asc^{-/-})}=0.4256$, $t(6)=0.85456$. CD4 $^{+}$ T in Spinal cord: $P_{(WT\ vs\ Nlrp3^{-/-})}=0.2260$, $t(6)=1.349$, $P_{(WT\ vs\ Asc^{-/-})}=0.6887$, $t(6)=0.4206$. Th17 in Brain: $P_{(WT\ vs\ Nlrp3^{-/-})}=0.6880$, $t(6)=0.4216$, $P_{(WT\ vs\ Asc^{-/-})}=0.6953$, $t(6)=0.4111$. Th17 in Spinal cord: $P_{(WT\ vs\ Nlrp3^{-/-})}=0.4683$, $t(6)=0.77416$, $P_{(WT\ vs\ Asc^{-/-})}=0.6429$, $t(6)=0.4879$. (d) EAE scores of Type-B EAE mice

with or without IFN β treatment. $n=5$. AUC between 0–30 dpi. $P_{(Type-A)}=0.0002$, $t(5)=6.668$, $P_{(Type-B)}=0.6514$, $t(6)=0.4753$. Treatment condition is described in Experimental Procedures. **(e, f)** Serum levels of IL-1 β (e) and IFN β (f) in naïve mice, Type-A and Type-B EAE mice at 9-dpi. $n=7$. IL-1 β : $P_{(Naïve vs Type-A)}=0.0327$, $t(13)=2.389$, $P_{(Naïve vs Type-B)}=0.1697$, $t(14)=1.448$, $P_{(Type-A vs Type-B)}=0.0284$, $t(13)=2.4912$. Naïve ($n=8$), Type-A ($n=7$), Type-B ($n=8$). IFN β : $P_{(Naïve vs Type-A)}=0.7024$, $t(12)=0.3914$, $P_{(Naïve vs Type-B)}=0.0339$, $t(12)=2.393$, $P_{(Type-A vs Type-B)}=0.0409$, $t(12)=2.29$. **(g)** EAE scores of WT and *Nlrp3*^{-/-} mice immunized with a Type-A EAE induction method with MHV68 infection (left panel); and WT Type-A EAE mice infected with MHV68 with or without IFN β treatment (right panel). MHV68 (10^5 pfu/mouse) was *i.v.* administered at the same time as Type-A EAE immunization. $n=5$. **(h)** Cell number ratios shown as brain-infiltrated cells divided by spinal-cord infiltrated cells ($n=7$). $P_{(Total)}=0.0166$, $t(12)=2.78$, $P_{(CD4)}<0.0074$, $t(12)=3.216$, $P_{(Th17)}=0.049$, $t(12)=3.436$, $P_{(Th1)}=0.0193$, $t(12)=2.701$, $P_{(CD8)}=0.098$, $t(12)=3.067$, $P_{(B)}=0.0062$, $t(12)=3.311$, $P_{(DC)}=0.0049$, $t(12)=3.436$, $P_{(PMN)}=0.0051$, $t(12)=3.413$, $P_{(Mac)}=0.0112$, $t(12)=2.992$. **(i)** Representative LFB-stained images with red arrows indicating regions of demyelination. All the CNS samples were harvested at 17-dpi. **(j)** T2 FLAIR MRI analysis of brain obtained from mice at 18-dpi. Yellow arrows indicate cortical region and external capsule. Image from Type B EAE mice exhibits the potential loss of myelin. *; $p<0.05$. All scale bars, 200 μ m. All statistical analyses in this figure were performed by two-tailed unpaired Student's *t*-test. All the experimental data and images are representatives from at least 2 similar experiments for each.




Figure 2. mLT is a key initiator of Type-B EAE

(a) Expression levels of *Lta* mRNA in DCs obtained from DLNs of naïve mice or mice at 9-dpi. ($n=3$). $P_{(Naive\ vs\ Type-A)}=0.2646$, $t(4)=1.296$, $P_{(Naive\ vs\ Type-B)}=0.0042$, $t(4)=5.88$, $P_{(Type-A\ vs\ Type-B)}=0.0027$, $t(4)=6.61$. (b) Percentages of DCs, positive for cell surface LTA expression, in DLNs of naïve mice or mice with EAE at 9-dpi, determined by flow cytometry. ($n=4$). $P_{(Naive\ vs\ Type-A)}=0.0253$, $t(6)=2.96$, $P_{(Naive\ vs\ Type-B)}=0.0109$, $t(6)=3.637$, $P_{(Type-A\ vs\ Type-B)}=0.0277$, $t(6)=2.891$. (c) Methylation analysis by bisulfite conversion with DCs obtained from DLNs, pooled from eight WT mice, Type-A and Type-B EAE at 9-dpi. Methylated and unmethylated CpG were shown with black and gray boxes, respectively. (d) EAE scores of WT mice after Type-A and Type-B induction with or without LT β R-Fc treatment. ($n=5$). (e) *Nlrp3*^{-/-} mice were immunized with the Type-A EAE induction method and treated with or without rLT. rLT (10 μ g/kg) was *i.p.* administrated daily between

0–9 dpi. *n*=5. **(f)** rLT-treated WT B6 mice induced for Type-A EAE were treated with or without IFN β (*n*=5). **(g)** Ratio of infiltrated cell numbers in the brain versus spinal cord at 17-dpi. Type-A EAE group (*n*=6), rLT-treated Type-A EAE group (*n*=7). $P_{(Total)}$ =0.0082, $t(11)$ =3.22, $P_{(CD4)}$ =0.0024, $t(11)$ =3.909, $P_{(Th17)}$ =0.0131, $t(11)$ =2.953, $P_{(Th1)}$ =0.0109, $t(11)$ =3.058, $P_{(CD8)}$ =0.0480, $t(11)$ =2.225, $P_{(B)}$ =0.1762, $t(11)$ =1.445, $P_{(DC)}$ =0.1020, $t(11)$ =1.784, $P_{(PMN)}$ =0.3260, $t(11)$ =1.027, $P_{(Mac)}$ =0.1737, $t(11)$ =1.455. **(h)** *Lta* mRNA expression in DCs treated with rIL-17 (10 ng/ml) or rIFN γ (10 ng/ml) for 3h. DCs were obtained from naïve WT mice. (*n*=3). $P_{(rIFN\gamma)}$ =0.8433, $t(4)$ =0.2108, $P_{(rIL-17)}$ =0.0295, $t(4)$ =3.317. **(i)** Th17-mediated passive EAE in WT (with or without LT β R-Fc treatment) and *Asc*^{-/-} mice (*n*=5). All statistical analyses in this figure were performed by two-tailed unpaired Student's *t*-test. *; $p < 0.05$. All the experimental data sets, except for (c), are representatives from at least 2 similar experiments for each.




Figure 3. Gene expression profile of CD4⁺ T cells between Type-A and Type-B EAE
 CD4⁺ T cells were FACS-purified from spleens at 9-dpi and submitted for the RNA-seq analysis. **(a)** Heatmap of 1,846 differentially expressed genes ($P < 0.05$; $\log_2FC > 1$ or < -1) between CD4⁺ T cells from Type-A and Type-B EAE mice. **(b)** Scatter plot comparing transcriptome. **(c)** Selected genes from pools with $P < 0.01$, $\log_2FC > 1$ or < -1 , and a $\log_2CPM > 1$. **(d)** mRNA levels of *Cxcr2*, *Cxcr1* and *Ltbr* in splenic CD4⁺ T cells obtained from naïve mice and mice with Type-A or Type-B EAE induction at 9-dpi determined by qPCR. ($n=3$). *Cxcr2*: $P_{(Naive vs Type-A)}=0.0231$, $t(4)=3.583$, $P_{(Naive vs Type-B)} < 0.0001$, $t(4)=23.22$, $P_{(Type-A vs Type-B)} < 0.0001$, $t(4)=22.75$. *Cxcr1*: $P_{(Naive vs Type-A)}=0.5999$, $t(4)=0.5689$, $P_{(Naive vs Type-B)}=0.0015$, $t(4)=7.806$, $P_{(Type-A vs Type-B)}=0.0036$, $t(4)=6.119$. *Ltbr*: $P_{(Naive vs Type-A)}=0.0170$, $t(4)=3.937$, $P_{(Naive vs Type-B)}=0.0091$, $t(4)=4.733$, $P_{(Type-A vs Type-B)}=0.0333$, $t(4)=3.188$. **(e)** Levels of *Cxcr2*, *Cxcr1* and *Ltbr* mRNA in CD4⁺

T 6h after rLT1 treatment at indicated concentrations. ($n=3$). $P_{(C_{xcr2})} < 0.0001$, $t(4)=19.36$, $P_{(C_{xcr1})} < 0.0001$, $t(4)=16.09$, $P_{(L_{ibr})}=0.0116$, $t(4)=4.413$. All statistical analyses in this figure were performed by two-tailed unpaired Student's t -test. Data sets (d, e) are representatives from at least 2 similar experiments for each.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Expression of *Cxcr2*, *Cxcr1*, and *Ltbr* in IFN β -resistant EAE and MS

(a) Cell numbers for indicated cell populations in DLNs and spleen at 9-dpi ($n=4$) from mice with either Type-A or Type-B EAE. DLNs: $P_{(Total)}=0.0314$, $t(6)=2.795$, $P_{(CD4)}=0.8376$, $t(6)=0.2141$, $P_{(CD8)}=0.2798$, $t(6)=1.188$, $P_{(B)}=0.0078$, $t(6)=3.921$, $P_{(DC)}=0.9606$, $t(6)=0.05144$, $P_{(Mac)}=0.0469$, $t(6)=2.495$, $P_{(PMN)}=0.1138$, $t(6)=1.851$, $P_{(Th17)}=0.5671$, $t(6)=0.6053$, $P_{(Th1)}=0.4813$, $t(6)=0.7506$, $P_{(Treg)}=0.9888$, $t(6)=0.01458$. Spleen: $P_{(Total)}=0.0307$, $t(6)=2.813$, $P_{(CD4)}=0.7759$, $t(6)=0.2978$, $P_{(CD8)}=0.0729$, $t(6)=0.4435$, $P_{(B)}=0.0046$, $t(6)=4.403$, $P_{(DC)}=0.2555$, $t(6)=1.326$, $P_{(Mac)}=0.0540$, $t(6)=2.703$, $P_{(PMN)}=0.0104$, $t(6)=3.673$, two-tailed unpaired Student's t -test. (b) Proportions of CXCR2-positive cells and MFI of CXCR2 staining in splenic CD4⁺ T cells obtained from naïve mice and mice with Type-A or Type-B EAE induction at 9-dpi determined by flow cytometry. ($n=4$). %: $P_{(Naive vs Type-A)}=0.7071$, $t(6)=0.3942$, $P_{(Naive vs Type-B)}=0.0053$, $t(6)=4.255$, $P_{(Type-A vs Type-B)}=0.0067$, $t(6)=4.051$. MFI: $P_{(Naive vs Type-A)}=0.0067$, $t(4)=5.151$, $P_{(Naive vs Type-B)}=0.0006$, $t(4)=9.794$, $P_{(Type-A vs Type-B)}=0.0024$, $t(4)=6.843$, two-tailed unpaired Student's t -test. (c) Relative expression of *CXCR2*, *CXCR1* and *LTBR* normalized by *VCAM1* in total PBMCs from IFN β -responder and non-responder MS patients. One circle denotes one patient. ($n=18$). $P_{(CXCR2)}=0.0435$, $P_{(CXCR1)}=0.0224$, $P_{(LTBR)}=0.0129$, Mann-Whitney U test. *; $p<0.05$. All the experimental data sets, except for (c), are representatives from at least 2 similar experiments for each.




Figure 5. Involvement of the CXCL1 and CXCR2 in development of Type-B EAE and Type-A EAE with MHV68 infection

(a) Transwell migration assay towards rCXCL1 using splenic CD4⁺ T cells harvested from indicated mice. $n=4$. (b) Levels of CXCL1 in serum from naïve mice or mice with Type-A or Type-B EAE mice on 9-dpi determined by ELISA. Naïve ($n=5$), Type-A ($n=3$), Type-B ($n=5$). $P_{(Naïve vs Type-A)}=0.8676$, $t(6)=0.174$, $P_{(Naïve vs Type-B)}=0.0059$, $t(8)=3.722$, $P_{(Type-A vs Type-B)}=0.0334$, $t(6)=2.749$. (c) CXCL1 staining in the choroid plexus on 9-dpi. Scale bars, 20 μ m. (d, e) Levels of CXCL1 in serum from Type-B EAE with or without LT β R-Fc treatment on 9-dpi. $n=4$. $P=0.0174$, $t(6)=3.252$. Scale bars, 20 μ m. (f) Score of Type-A or Type-B EAE treated with or without SB225002. Vehicle-treated group ($n=5$), SB225002-treated group ($n=7$). $P=0.002$, $t(10)=5.634$. (g) EAE score in *Lck-Cre Cxcr2^{fl/fl}* mice (CXCR2-cKO) and *Cxcr2^{fl/fl}* mice (control). $*$; $p<0.05$. ($n=8$). $P=0.0192$, $t(14)=2.646$.

(h) Representative LFB-stained images with red lines indicating regions of demyelination at 17-dpi. Scale bars, 200 μ m. **(i)** Percentages LT α ⁺ DCs in DLNs and CXCR2⁺CD4⁺T cells in spleens of mice at 9-dpi immunized with a Type-A EAE induction method with or without MHV68 infection. ($n=4$). $P=0.0002$, $t(6)=7.72$, $P=0.0026$, $t(6)=4.931$. **(j)** Serum levels of IL-1 β and IFN β at 9-dpi in naïve mice and mice immunized with a Type-A EAE induction method with or without MHV68 infection. $n=4$. IL-1 β : $P_{(Naive\ vs\ Type-A)}=0.0152$, $t(6)=3.361$, $P_{(Naive\ vs\ Type-A+MHV68)}=0.3925$, $t(6)=0.9212$, $P_{(Type-A\ vs\ Type-A+MHV68)}=0.0259$, $t(6)=2.942$. CXCL1: $P_{(Naive\ vs\ Type-A)}=0.8498$, $t(6)=0.1978$, $P_{(Naive\ vs\ Type-A+MHV68)}=0.0174$, $t(6)=3.252$, $P_{(Type-A\ vs\ Type-A+MHV68)}=0.0205$, $t(6)=3.124$. **(k)** EAE scores of mice Type-A-induced mice with MHV68 infection. Treatment was with either LT β R-Fc or SB225002. Negative control groups did not receive the treatments ($n=4$). All statistical analyses in this figure were performed by two-tailed unpaired Student's t -test. All the experimental data and images are representatives from at least 2 similar experiments for each.




Figure 6. Persistent disease severity and spinal transected neurites in Type-B EAE mice (a) EAE scores in WT mice after Type-A and Type-B EAE induction ($n=9$). (b) Representative LFB-stained images of spinal cord sections. Yellow lines indicate regions of demyelination. (c) Representative silver staining images to show neurons in spinal cord sections. Areas within the yellow rectangles were enlarged. Scale bars in (b) and (c, original size picture), 200 μ m, and in (c, magnified pictures), 50 μ m. (d) Motor neuron stereology. Total Nissl⁺ and α -motor neuron in lumbar region of the spinal ventral horn were evaluated. *: $p < 0.05$. Total motor neuron number: $P=0.0001$, $F_{20.61}$. α motor neuron number: $P=0.0032$, $F=11.65$, by Bonferroni's Method ($n=6$). All the CNS samples were harvested on 70-dpi. All the experimental data and images are representatives from at least 2 similar experiments for each.




Figure 7. Type-B EAE-derived T cells cause neuronal retraction

(a–c) CD4⁺ T cells were obtained from spleens of either naïve, Type-A EAE, or Type-B EAE mice; then, co-cultured with neurons. Representative images of hippocampal neuron stained with MAP2 (red) and DAPI (blue) one day after co-culture with indicated CD4⁺ T cells (a). (b) Average neurite lengths (left panel) and distributions of neurite lengths (right panel) in T cell–neuron co-culture ($n=3$, measured at least 18 neurons per condition).

$P_{(Naive\ vs\ Type-A)}=0.5044$, $t(4)=0.7324$, $P_{(Naive\ vs\ Type-B)}=0.0005$, $t(4)=10.11$,

$P_{(Type-A\ vs\ Type-B)}=0.0017$, $t(4)=7.54$. Average numbers of axon and dendrite branches per neuron (left panel) and distributions of branch numbers (right panel)(c). ($n=3$, measured at least 18 neurons per condition).

$P_{(Naive\ vs\ Type-A)}=0.1966$, $t(4)=1.548$,

$P_{(Naive\ vs\ Type-B)}=0.0007$, $t(4)=9.387$, $P_{(Type-A\ vs\ Type-B)}=0.0008$, $t(4)=9.22$. **(d)** mRNA expression levels of genes encoding proteins in semaphorin and ephrin families in CD4⁺ T cells from Type-A and Type-B EAE mice at 9-dpi. Data denote as ratio of gene expression in CD4⁺ T cells from naïve mice. ($n=3$) $P_{(Sema3d)}=0.0599$, $t(2)=3.899$, $P_{(Sema3f)}=0.8657$, $t(2)=0.1916$, $P_{(Sema4a)}=0.4043$, $t(2)=1.049$, $P_{(Sema4d)}=0.0792$, $t(2)=3.339$, $P_{(Sema6b)}=0.0175$, $t(5)=34.915$, $P_{(Efna1)}=0.0318$, $t(2)=5.472$, $P_{(Efna2)}=0.4476$, $t(2)=0.9373$, $P_{(Efna5)}=0.2419$, $t(2)=1.644$, $P_{(Efnb1)}=0.0658$, $t(2)=3.704$, $P_{(Efnb2)}=0.8169$, $t(2)=0.2634$, $P_{(Efnb3)}=0.6110$, $t(2)=0.5059$. “*n.d.*” means “not detectable”. **(e, f)** CD4⁺ T cells were obtained from either naïve or Type-B EAE mice, and *Sema6b* mRNA was knocked down by shRNA in the indicated group. T cells were then co-cultured with neurons. Representative images of neurons stained with MAP2 (red) and DAPI (blue)(e). $P_{(Naive\ T\ vs\ Type-B\ T+Control\ shRNA)}=0.0096$, $t(4)=4.657$, $P_{(Naive\ T\ vs\ Type-B\ T+Sema6b\ shRNA)}=0.3377$, $t(4)=1.088$, $P_{(Type-B\ T+Control\ shRNA\ vs\ Type-B\ T+Sema6b\ shRNA)}=0.0169$, $t(4)=3.944$. Average neurite lengths (f, left panel) and average numbers of axon and dendrite branches per neuron (f, right panel). ($n=3$, measured at least 18 neurons per condition). $P_{(Naive\ T\ vs\ Type-B\ T+Control\ shRNA)}=0.0233$, $t(4)=3.573$, $P_{(Naive\ T\ vs\ Type-B\ T+Sema6b\ shRNA)}=0.6259$, $t(4)=0.5273$, $P_{(Type-B\ T+Control\ shRNA\ vs\ Type-B\ T+Sema6b\ shRNA)}=0.0215$, $t(4)=3.662$. **(g)** Expression levels of *Sema6b* mRNA in CD4⁺ T cells isolated from Type-A EAE mice with or without rLT treatment for 6h. ($n=3$) $P=0.0039$, $t(4)=5.981$. **(h)** Representative images of MAP2-stained neurons in co-culture with rLT-treated T cell. Average neurite lengths and numbers of axon and dendrites branches per neuron were analyzed and shown. One-hundred % denotes the values obtained from neurons co-cultured with naïve T cells. $n=3$. All scale bars in (a, e, h), 50 μ m. $P_{(length)}=0.0211$, $t(4)=3.686$. $P_{(number)}=0.017$, $t(4)=7.544$. All statistical analyses in this figure were performed by two-tailed unpaired Student’s *t*-test. All the experimental data and images are representatives from at least 2 similar experiments for each.